AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT06039683
- Locations
- 🇦🇪
Research Site, Al Ain, United Arab Emirates
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Phase 3
Active, not recruiting
- Conditions
- Uncontrolled HypertensionResistant Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 796
- Registration Number
- NCT06034743
- Locations
- 🇻🇳
Research Site, Hochiminh city, Vietnam
PRostate Olaparib Real World Evidence Study
Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06031805
- Locations
- 🇫🇷
Research Site, Vantoux, France
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 372
- Registration Number
- NCT06023589
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 320
- Registration Number
- NCT06020014
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
Phase 3
Recruiting
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- Combination Product: AnifrolumabOther: Placebo
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 460
- Registration Number
- NCT06015737
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Phase 3
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 280
- Registration Number
- NCT06008093
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Gastric CancerGastro-esophageal Junction CancerPancreatic Ductal AdenocarcinomaEsophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT06005493
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
🇬🇧Research Site, Wirral, United Kingdom
PICAROS - Acalabrutinib RWE on 1L CLL in Spain
Active, not recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 192
- Registration Number
- NCT05999877
- Locations
- 🇪🇸
Research Site, Murcia, Region De Murcia, Spain
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Phase 3
Recruiting
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 900
- Registration Number
- NCT05984277
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath